stackBETA

Daily

  • Log

Verify

  • Cabinet · stacks
  • Vials · inventory

Build

  • Reconstitution

Plan

  • Can I get it?
  • Compare
  • Synergy check

Learn

  • Encyclopedia
  • Common stacks
  • Pulse
  • Methodology

Info

  • Partners & programs

Stack · v0.1 beta

stackBETAv0.1
LogEncyclopediaPulse
MethodologyPartners & programs
← Back to your stack
Monograph
RESEARCH GREYP-069
Recovery

VIP (Vasoactive Intestinal Peptide)

28-aa peptide of the secretin/glucagon family. Modulates vascular tone, anti-inflammatory cytokine balance, neuroimmune crosstalk. Central to the Shoemaker 'biotoxin / CIRS' protocol — used as nasal spray for chronic-inflammatory-response syndrome.

ExperimentalRecovery
Typical dose50 mcg per nostril
Frequency4× daily, intranasal
Half-life0.5h
Citations indexed38
100%50%0%030min1h1.5h2h2.5ht½ 30minPK · plasma

How it clearsHalf cleared in ~30min. Most (~96%) gone by ~2.5h.

DeliveryInjectable
Half-life~30min
EvidenceExperimental
Citations38
Similar compounds
Stack Pro · compare side-by-side

Compare these compounds

Mechanism, evidence, legal path, cost — all side-by-side.

→
Synergy checkCompareReconstitution calc
Research grey

This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.

Mechanism

Shoemaker's CIRS (Chronic Inflammatory Response Syndrome) protocol uses VIP nasal spray as the final step after biotoxin exposure remediation. The CIRS framework is controversial in mainstream medicine — not in DSM/ICD, no large RCT validation — but has a dedicated patient + practitioner community including veterans with mold-exposure illness, post-COVID-long syndromes, Lyme co-infection cohorts. VIP has FDA-approved indications via inhaled formulation (aviptadil/Zyesami) tested in COVID-19 ARDS — emergency-use trials in 2020-21 showed mortality signal in subgroup analyses, mixed in primary endpoint.

Specifics
Low energy / fatigueBrain fogMood
Caveats

CIRS framework is contested in mainstream medicine — Stack catalogs VIP because the cohort runs it, not as endorsement of the diagnostic framework. Practitioners require Shoemaker-protocol biotoxin remediation BEFORE VIP — using VIP without that sequencing reportedly worsens symptoms in some users. Compounding pharmacy quality varies severely on nasal VIP.

Evidence levelExperimental
Regulatory status503A-compounded · CIRS protocol is non-mainstream-medicine · aviptadil (inhaled VIP) was investigational for COVID-19 ARDS
DNA / pharmacogenomicsModerate — HLA-DR/DQ haplotypes predict susceptibility to Shoemaker's CIRS — the Shoemaker framework relies on HLA genotyping as part of diagnosis.
Your data · empty

Upload your data to see how it relates to VIP.

Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.

Upload in /history→
Claims & evidence

Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.

  • DMechanistic / anecdotal

    VIP (Vasoactive Intestinal Peptide) — primary mechanism: 28-aa peptide of the secretin/glucagon family. modulates vascular tone, anti-inflammatory cytokine balance, neuroimmune crosstalk. central to the shoemaker 'biotoxin / cirs' protocol — used as nasal spray for chronic-inflammatory-response syndrome.

    2 supporting referencesVerified 13d ago
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • ReviewEN
    REVIEWSelf-fundedVerified 13d ago
    PubMed — Shoemaker CIRS VIP protocol review
  • PubMedEN
    RCTIndustry-fundedVerified 13d ago
    PubMed — Aviptadil COVID-19 ARDS trial
RESEARCH GREYP-069

503A-compounded · CIRS protocol is non-mainstream-medicine · aviptadil (inhaled VIP) was investigational for COVID-19 ARDS

Can I get it? →
Reconstitution calculatorVIP

Pre-filled with this compound's published dose range: 50 mcg per nostril · 4× daily, intranasal

Concentration2.50 mg/mL
Draw volume0.020 mL
Insulin syringe2.0 u
Doses per vial100
U-100 syringe — fill to indicatorU-100 · 1 mL
0u25u50u75u100u
Watch

Draw volume is below 5 units — hard to measure accurately on most syringes. Consider adding more BAC water to dilute, or moving to a smaller syringe.

Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.

No field reports yet

Field reports are added as users share their real-world protocols.

VIP50 mcg per nostril · 4× daily, intranasal

Next visit & citations

Handoff & sources

Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.

Open Dr PassportMethodologyResearch tableClinician primer
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesPartners & programsWho Stack is forFor creatorsFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.
TodayLibrary
ToolsMe